Dyne Therapeutics Quarterly Income Statement
NASDAQ: DYNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.64+0.27 (+1.65%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Dyne Therapeutics revenue and earnings
Dyne Therapeutics reported a net loss of $178.6 million, compared with a loss of $110.9 million a year earlier. Diluted earnings per share came in at -$1.08.
Summary generated from market data by MetaCap's automated system. Methodology
Dyne Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 181.66M | 125.28M | 116.13M | 113.89M | 115.79M | 122.37M | 97.11M | 105.66M | 71.96M | 69.16M | 67.69M | 62.27M |
| Research & Development | 152.17M | 100.89M | 95.43M | 97.22M | 99.24M | 106.45M | 81.81M | 92.80M | 62.26M | 44.54M | 58.84M | 55.25M |
| Operating Income | -181.66M | -125.28M | -116.13M | -113.89M | -115.79M | -122.37M | -97.11M | -105.57M | -71.96M | -69.16M | -67.69M | -62.27M |
| Interest Expense | — | — | — | 2.90M | 94.00K | — | — | 0 | — | — | — | — |
| Other Income (Expense) | 3.10M | 4.42M | 4.17M | 5.85M | 4.93M | 7.01M | 7.57M | 8.53M | 6.86M | 3.51M | 1.05M | 2.06M |
| Net Income | -178.56M | -120.85M | -111.95M | -108.04M | -110.86M | -115.36M | -89.54M | -97.13M | -65.10M | -65.65M | -66.64M | -60.21M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.08 | -0.73 | -0.69 | -0.76 | -0.97 | -1.05 | -0.90 | -0.96 | -0.70 | -0.81 | -1.10 | -0.99 |
| EPS (Diluted) | -1.08 | -0.73 | -0.69 | -0.76 | -0.97 | -1.05 | -0.90 | -0.96 | -0.70 | -0.81 | -1.10 | -0.99 |
| EBITDA | -181.06M | -124.73M | -115.61M | -113.39M | -115.29M | -121.87M | -96.66M | -105.17M | -71.56M | -68.77M | -67.29M | -61.87M |
This table shows 12 quarterly periods of Dyne Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 11 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow DYN's reporting calendar. What is a income statement?